Literature DB >> 16990643

Etiology and impact of cytomegalovirus disease on solid organ transplant recipients.

Lisa M McDevitt1.   

Abstract

PURPOSE: The characteristics, etiology, natural history, and direct and indirect effects of CMV disease in solid organ transplant recipients are described.
SUMMARY: CMV is a common herpesvirus that may be present in the donor or recipient of a solid organ transplant. Even though it is rarely pathogenic in healthy patients, transplant recipients are at risk for CMV viremia and symptomatic disease due to their immune-suppressed status. In addition to symptoms directly attributed to active disease, CMV can have a variety of indirect effects. Indirect effects may include additional infectious complications, posttransplant lymphoproliferative disease, allograft rejection, allograft loss, or death. The three most prevalent risk factors for CMV infection are CMV seronegativity in a recipient of an organ from a CMV-seropositive donor, the type of organ transplanted, and the degree of immune suppression. CMV prophylaxis is effective at preventing disease, but may result in a delayed onset where CMV disease occurs once the prophylaxis is stopped.
CONCLUSION: Knowledge of risk factors for CMV infection and disease, the natural history in transplant recipients, and its direct and indirect effects will help clinicians make appropriate decisions regarding the use of preventive strategies.

Entities:  

Mesh:

Year:  2006        PMID: 16990643     DOI: 10.2146/ajhp060377

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.637


  10 in total

1.  Introduction: disease overview and risk factors.

Authors: 
Journal:  P T       Date:  2010-03

2.  The impact of donor viral replication at transplant on recipient infections posttransplant: a prospective study.

Authors:  Priya S Verghese; David O Schmeling; Jennifer A Knight; Arthur J Matas; Henry H Balfour
Journal:  Transplantation       Date:  2015-03       Impact factor: 4.939

Review 3.  Exosomes in Viral Disease.

Authors:  Monique R Anderson; Fatah Kashanchi; Steven Jacobson
Journal:  Neurotherapeutics       Date:  2016-07       Impact factor: 7.620

4.  Late-onset CMV disease following CMV prophylaxis.

Authors:  C Donnelly; F Kennedy; C Keane; K Schaffer; P A McCormick
Journal:  Ir J Med Sci       Date:  2009-04-02       Impact factor: 1.568

Review 5.  Natural killer cells in lung transplantation.

Authors:  Daniel R Calabrese; Lewis L Lanier; John R Greenland
Journal:  Thorax       Date:  2018-10-31       Impact factor: 9.139

Review 6.  CMV Immunoglobulins for the Treatment of CMV Infections in Thoracic Transplant Recipients.

Authors:  Uwe Schulz; Paolo Solidoro; Veronika Müller; Attila Szabo; Jens Gottlieb; Heinrike Wilkens; Frank Enseleit
Journal:  Transplantation       Date:  2016-03       Impact factor: 4.939

7.  Optimal Use of Ganciclovir and Valganciclovir in Transplanted Patients: How Does It Relate to the Outcome?

Authors:  Maryam Mozaffar; Shahrzad Shahidi; Marjan Mansourian; Shirinsadat Badri
Journal:  J Transplant       Date:  2018-09-17

8.  Human Cytomegalovirus Seropositivity and Viral DNA in Breast Tumors Are Associated with Poor Patient Prognosis.

Authors:  Zelei Yang; Xiaoyun Tang; Maria Eloisa Hasing; Xiaoli Pang; Sunita Ghosh; Todd P W McMullen; David N Brindley; Denise G Hemmings
Journal:  Cancers (Basel)       Date:  2022-02-23       Impact factor: 6.639

9.  Ganciclovir use evaluation in kidney transplantation departments.

Authors:  Maryam Mozaffar; Shahrzad Shahidi; Shirinsadat Badri
Journal:  J Res Pharm Pract       Date:  2016 Jul-Sep

10.  Treatment of Cytomegalovirus Infection with Cidofovir and CMV Immune Globulin in a Lung Transplant Recipient.

Authors:  Heinrike Wilkens; Martina Sester
Journal:  Case Rep Transplant       Date:  2016-01-13
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.